公开(公告)号：US20140170250A1

公开(公告)日：2014-06-19

申请号：US14133213

申请日：2013-12-18

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Horng PAN ,  Hsin-Jan YAO ,  Mei-Wei LIN ,  I-Huang LU ,  Hsin-Chieh WU ,  Hsiang-Wen TSENG ,  Ching-Huai KO ,  Chun-Chung WANG ,  Zong-Keng KUO ,  Shyh-Horng LIN ,  Yi-Cheng CHENG ,  Tien-Soung TONG

IPC: A61K36/14 ,  A61K31/357

CPC classification number: A61K31/365 ,  A61K31/7048 ,  A61K36/14 ,  A61K2300/00

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of an extract of Juniperus chinensis or an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract translation: 本公开内容提供了用于抑制血管生成的药物组合物，包括有效量的桧属提取物或有效量的木酚素作为有效成分。 药物组合物还可以包括药学上可接受的载体或盐。 本公开还提供了抑制血管发生的方法，包括给予有效量的桧属提取物或有效量的木脂素作为有效成分，用于抑制有需要的受试者的血管生成。

公开(公告)号：US20190000776A1

公开(公告)日：2019-01-03

申请号：US16023940

申请日：2018-06-29

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Kuo-Kuei HUANG ,  I-Hong PAN ,  Shu-Fang WEN ,  Meng-Nan LIN ,  I-Huang LU ,  Zong-Keng KUO ,  Chu-Hsun LU ,  Tze-Chung LEE ,  Ya-Yan YANG ,  Jia-Horng LIAW

IPC: A61K31/047 ,  A61K31/222 ,  A61K31/075 ,  A61K31/122 ,  A61K31/343 ,  A61K9/14 ,  A61K9/08 ,  A61K47/02 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/40 ,  A61P25/28 ,  A61P37/00

Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, —SO2CH3, —(C═O)—CH3 or —(C═O)—NH2.

公开(公告)号：US20160008319A1

公开(公告)日：2016-01-14

申请号：US14864203

申请日：2015-09-24

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Horng PAN ,  Hsin-Jan YAO ,  Mei-Wei LIN ,  I-Huang LU ,  Hsin-Chieh WU ,  Hsiang-Wen TSENG ,  Ching-Huai KO ,  Chun-Chung WANG ,  Zong-Keng KUO ,  Shyh-Horng LIN ,  Yi-Cheng CHENG ,  Tien-Soung TONG

IPC: A61K31/365 ,  A61K31/7048

CPC classification number: A61K31/365 ,  A61K31/7048 ,  A61K36/14 ,  A61K2300/00

Abstract: The disclosure provides a pharmaceutical composition for inhibiting angiogenesis, including an effective amount of a lignan as an effective ingredient. The pharmaceutical composition may further include a pharmaceutically acceptable carrier or salt. The disclosure also provides a method for inhibiting angiogenesis, including administering an effective amount of a lignan as an effective ingredient for inhibiting angiogenesis to a subject in need thereof.

Abstract translation: 本公开提供了用于抑制血管发生的药物组合物，包括有效量的木脂素作为有效成分。 药物组合物还可以包括药学上可接受的载体或盐。 本公开还提供了一种抑制血管生成的方法，包括给予有效量的木脂素作为有效成分，用于抑制有需要的受试者的血管生成。

公开(公告)号：US20220249395A1

公开(公告)日：2022-08-11

申请号：US17727301

申请日：2022-04-22

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Kuo-Kuei HUANG ,  I-Hong PAN ,  Shu-Fang WEN ,  Meng-Nan LIN ,  I-Huang LU ,  Zong-Keng KUO ,  Chu-Hsun LU ,  Tze-Chung LEE ,  Ya-Yan YANG ,  Jia-Horng LIAW ,  Pei-Hsin LIN

IPC: A61K31/047 ,  A61K31/215 ,  A61K31/335 ,  A61K9/50 ,  A61K31/352 ,  A61K9/00 ,  A61K31/045 ,  A61P37/00 ,  A61P25/28 ,  A61K9/08 ,  A61K9/14 ,  A61K31/075 ,  A61K31/122 ,  A61K31/222 ,  A61K31/343 ,  A61K47/02 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/40

Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C═O)-alkyl, —(C═O)-aryl, —(C═O)-alkyl-aryl, —(C═O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, O2CH3, —(C═O)—CH3 or (C═O)—NH2.

公开(公告)号：US20210015882A1

公开(公告)日：2021-01-21

申请号：US17036985

申请日：2020-09-29

Applicant: Industrial Technology Research Institute

Inventor： Kuo-Kuei HUANG ,  I-Horng PAN ,  Ying-Fei TSAI ,  I-Huang LU ,  Chu-Hsun LU ,  Shu-Fang WEN ,  Zong-Keng KUO ,  Shu-Jiau CHIOU

IPC: A61K36/75 ,  A61K31/395 ,  A61K31/366 ,  A61K31/37 ,  A61K31/4015 ,  A61K31/404

Abstract: The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to Rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease and ulcerative colitis (UC).

公开(公告)号：US20240216454A1

公开(公告)日：2024-07-04

申请号：US18396942

申请日：2023-12-27

Applicant: Industrial Technology Research Institute

Inventor： Kuo-Kuei HUANG ,  I-Hong PAN ,  I-Huang LU ,  Shu-Fang WEN

IPC: A61K36/28 ,  A61P17/00

CPC classification number: A61K36/28 ,  A61P17/00 ,  A61K2236/331 ,  A61K2236/37 ,  A61K2236/39 ,  A61K2236/51 ,  A61K2236/53

Abstract: A method for treating dermatitis is provided. The method for treating dermatitis includes administering an effective amount of an Adenostemma lavenia extract or administering an effective amount of a pharmaceutical composition for treating dermatitis including an Adenostemma lavenia extract to a subject in need thereof, wherein the dermatitis comprises atopic dermatitis or contact dermatitis.

公开(公告)号：US20170258865A1

公开(公告)日：2017-09-14

申请号：US15416391

申请日：2017-01-26

Applicant: Industrial Technology Research Institute

Inventor： Kuo-Kuei HUANG ,  I-Horng PAN ,  Ying-Fei TSAI ,  I-Huang LU ,  Chu-Hsun LU ,  Shu-Fang WEN ,  Zong-Keng KUO ,  Shu-Jiau CHIOU

IPC: A61K36/75 ,  A61K31/404 ,  A61K31/4015 ,  A61K31/366 ,  A61K31/37

Abstract: The present disclosure provides a pharmaceutical composition for treating or alleviating an autoimmune disease and/or complication thereof and/or nephritis, including: an effective amount of an extract of a plant belonging to Rutaceae as an effective ingredient for treating or alleviating the autoimmune disease and/or complication thereof and/or nephritis, wherein the autoimmune disease is selected from a group consisting of lupus erythematosus, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease and ulcerative colitis (UC).

公开(公告)号：US20150050315A1

公开(公告)日：2015-02-19

申请号：US14323719

申请日：2014-07-03

Applicant: Industrial Technology Research Institute

Inventor： I-Horng PAN ,  Shu-Fang WEN ,  Ming-Han LI ,  Hsin-Jan YAO ,  Hsin-Chieh WU ,  I-Huang LU ,  Joung-Liang LAN ,  Der-Yuan CHEN ,  Chi-Chien LIN ,  Ching LU

IPC: A61K36/07

CPC classification number: A61K36/07

Abstract: The disclosure provides a method for modulating Th17 cells, including: administering an Antrodia cinnamomea (also named Antrodia camphorata or Taiwanofungus camphoratus) extract to a subject in need thereof, wherein the Antrodia cinnamomea extract has an effect of modulating Th17 cells. The Antrodia cinnamomea extract may include a fruiting body extract of Antrodia cinnamomea or a mycelium extract of Antrodia cinnamomea.

Abstract translation: 本公开内容提供了一种调节Th17细胞的方法，包括：向有需要的受试者施用Antrodia cinnamomea（也称为樟芝或番茄樟脑）提取物，其中所述番茄红素提取物具有调节Th17细胞的作用。 梧桐提取物可以包括樟子松的果实提取物或肉桂樟子的菌丝体提取物。